NUBEQA (Bayer Australia Ltd)
Product name
NUBEQA
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
218 (255 working days)
Active ingredients
darolutamide
Registration type
EOI
Indication
NUBEQA is indicated for the treatment of patients with:
- metastatic hormone-sensitive prostate cancer (mHSPC) in combination with docetaxel